Genmab A/S (OTCMKTS:GNMSF – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $230.86 and traded as low as $191.84. Genmab A/S shares last traded at $191.84, with a volume of 11 shares changing hands.
Genmab A/S Trading Up 2.7 %
The firm’s 50-day moving average price is $207.03 and its 200 day moving average price is $230.86. The company has a market capitalization of $12.67 billion, a price-to-earnings ratio of 18.45 and a beta of 1.04.
About Genmab A/S
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Featured Articles
- Five stocks we like better than Genmab A/S
- Basic Materials Stocks Investing
- 3 Reasons Micron Stock Is Deeply Undervalued Right Now
- What is a Stock Market Index and How Do You Use Them?
- Inflation Persists, But So Do Stock Opportunities: Rally On
- Why Invest in High-Yield Dividend Stocks?
- Energy Transfer Fuels the Cloud: A Natural Gas Power Play
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.
